After Hours
$
8.47
Change
-0.06 -0.70%
Volume
Volume 1.58m
Mar 23, 2023, 7:58 p.m.
Quotes are delayed by 20 min
Previous close
$ 8.73
$ 8.53
Change
-0.20 -2.29%
Day low
Day high
$8.40
$8.83

52 week low
52 week high
$6.78
$11.45

Market cap
$9.96B
Average volume
8.73M
P/E ratio
N/A
Rev. per Employee
$404,986
EPS
-2.12
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on TEVA
-
Apple Is Not the Economy. Why the Fed’s More Bullish Than Tech.
- Barron's Online
-
Teva Pharmaceutical names pharma exec Richard Francis and president and CEO
- Steve Gelsi
-
New Teva CEO Richard Francis was CEO of Sandoz and Biogen exec
- Steve Gelsi
-
Teva CEO Kåre Schultz to retire on Dec. 31
- Steve Gelsi
-
Teva Pharmaceutical downgraded to underweight from neutral at J.P. Morgan
- Tomi Kilgore
-
Teva Is 'on the Way' to Leaving Opioid Litigation Behind, CEO Says
- Barron's Online
-
Teva Pharmaceutical upgraded to buy from neutral at BofA Securities
- Tomi Kilgore
-
AbbVie Stock Slips After Earnings, Charge for Potential Opioid Deal
- Barron's Online
-
$4.4 Billion Opioid Settlement Gives Teva Stock a Boost
- Barron's Online
-
Teva Stock Soars After Reaching $4.25 Billion Opioid Settlement
- Barron's Online
-
Teva to pay $75 mln over 15 years to settle opioid claims from W. Va., plus pay $8 mln in legal fees
- Steve Gelsi
-
Teva settlement with W. Va. also includes $27 mln worth of generic Narcan over 10 years
- Steve Gelsi
- Loading more headlines...
Analyst Ratings
-
Analysts Raise Ratings on Teva Stock on Ajovy’s FDA Approval
- MarketRealist.com
-
Why Teva’s Generic EpiPen Contribution Could Be Modest in 2018
- MarketRealist.com
-
Analysts Cut Target Prices on MYL Stock after Its Q2 2018 Results
- MarketRealist.com
Other News on TEVA
-
McKinsey Consulted VA While Advising Opioid Makers to Target Agency for Sales
- The Wall Street Journal Interactive Edition
-
Francisco Garcia Parames' Cobas Funds 4th-Quater Letter
- GuruFocus.com
-
Top 5 4th Quarter Trades of BECK MACK & OLIVER LLC
- GuruFocus.com
-
Top 5 4th Quarter Trades of MILLER VALUE PARTNERS, LLC
- GuruFocus.com
-
Top 5 3rd Quarter Trades of Exor Capital LLP
- GuruFocus.com
-
Top Trades of David Abrams' Firm in the 4th Quarter
- GuruFocus.com
-
Opioid Settlement Money Is Coming. Two Ohio Counties Differ on How to Spend It.
- The Wall Street Journal Interactive Edition
-
10-K: TEVA PHARMACEUTICAL INDUSTRIES LTD
- Edgar Online - (EDG = 10Q, 10K)
-
Humira Faces Competition From First U.S. Copycat
- The Wall Street Journal Interactive Edition
-
DEA Pressed ADHD-Drug Makers About Impact of Telehealth Firms on Surging Demand
- The Wall Street Journal Interactive Edition
-
World’s Top-Selling Drug Going Off Patent Means Big Bucks for Middlemen
- The Wall Street Journal Interactive Edition
-
Teva Pharmaceutical Names Richard Francis as CEO
- The Wall Street Journal Interactive Edition
-
Opioid reversal agent naloxone approvable for OTC use – FDA
- Seeking Alpha
-
Top 5 3rd Quarter Trades of DSC Advisors, L.P.
- GuruFocus.com
-
Teva slips as JPMorgan downgrades on growth concerns
- Seeking Alpha
-
BECK MACK & OLIVER LLC Buys 2, Sells 3 in 3rd Quarter
- GuruFocus.com
- Loading more headlines...
Press Releases on TEVA
-
Teva Pharmaceutical $TEVA Pivots Trading Plans and Risk Controls
- Stock Traders Daily
-
Teva Pharmaceutical $TEVA Investment Report
- Stock Traders Daily
-
Teva to Present at the Barclays Global Healthcare Conference
- BusinessWire - BZX
-
Teva Pharmaceutical ($TEVA) Trading Report
- Stock Traders Daily
-
Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026
- BusinessWire - BZX
-
How the price action of Teva Pharmaceutical (TEVA) is used to our Advantage
- Stock Traders Daily
-
Teva Pharmaceutical TEVA Trading Report
- Stock Traders Daily
-
Teva Reaches Agreement With Florida to Settle the State’s Price Fixing Claims
- BusinessWire - BZX
-
Teva Reports Fourth Quarter and Full Year 2022 Financial Results
- BusinessWire - BZX
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com